This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site



Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyOff-contract claimsAlliance Healthcare

Example content



AMSAMSAn introduction to antimicrobial stewardshipStewardshipSurveillanceRace against resistanceABSABSABS in practice Educational ResourcesAFSAFSShape the futureAFS in practiceImplementing an AFS programmeDiagnosticsGuidelinesCase studiesAll case studiesOur CommitmentOur CommitmentOur commitment to anti-infectivesHeritageSustainability
Our work in the community
Support & ResourcesSupport & ResourcesVideosMaterialsOnline LearningOnline LearningHomeINSPIRE To: Change the CourseLondon AMS SeriesNorth West England AMS SeriesInfectious Thinking Podcasts

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Infectious Thinking
Connecting Expertise Podcast
Series 1

Raising awareness of Antimicrobial Resistance (AMR), we present this new podcast series in which Professor Philippe Montravers and Dr Camilla Rodrigues welcome international experts to discuss the challanges and share expertise in managing multi-drug resistant infections in critically ill patients.

Episode 1: The Growing Threat of AMR

Expert guest Professor Peter Hawkey joins hosts Professor Montravers and Dr Rodrigues to explore the development and spread of AMR, how it should be managed and why stewardship and rapid diagnostics are important.

Episode 2: Act Fast Against CRE - cIAI

Guest speaker Dr Alex Soriano meets our hosts to look at the incidence of complicated intra-abdominal infections caused by CRE and the associated challenges in treating high-risk patients.

Episode 3: VAP's Happening. Now What?

Professor Antoni Torres joins our hosts to discuss the impact of COVID-19 on the number of multi-drug resistant ventilator-associated pneumonia cases especially Pseudomonas aeruginosa while assessing the treatment pathway and viable treatment options in VAP.

Episode 4: It Just Got Harder. A High Risk Paediatric Patient

Great Ormond Street Hospital's Dr Louis Grandjean, Dr James Hatcher and Orlagh McGarrity discuss treatment in high-risk paediatric complicated intra-abdominal infection cases, challenges of MDR Pseudomonas in this group and investigate available options to paediatric patients

Episode 5: Targeting CRE (HAP)

David Livermore talks to our hosts about CRE, its unique challenges in the treatment pathway for high-risk patients with HAP, using β-lactam/β-lactamase inhibitors for CRE infections and available treatment options for carbapenemases OXA-48 and KPC.

Episode 6: Habits Aside, Why Polymyxins?

The speakers weigh up treatment options for acute pyelonephritis with secondary bacteraemia due to CRE. They discuss polymyxin use in the critically ill and examine β-lactam/β-lactamase inhibitors as viable alternatives. With expert guest Professor Souha Kanj.

Educational Resources

We have a variety of educational resources aimed at supporting Healthcare Professsionals looking to enhance their knowledge of AMR and Stewardship.

Access ResourcesLoading
Access more antimicrobial stewardship resources

Get further information on antimicrobial stewardship including a variety of resources for antibacterial and antifungal stewardship on the Anti-infectives section of PfizerPro 

Visit Anti-InfectivesLoading


CRE, carbapenem resistant enterobacteriaceae; cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; AMR, Antimicrobial Resistance; AMS, Antimicrobial Stewardship; AFS, Antifungal Stewardship; ABS, Antibacterial Stewardship

Prescribing Information

Click here for ZAVICEFTA® (ceftazidime avibactam) prescribing informationClick here for MERONEM® (meropenem trihydrate) Prescribing Information
Click here for TAZOCIN® (piperacillin sodium, tazobactam sodium) Prescribing InformationClick here for TYGACIL®(tigecycline) Prescribing Information in Great Britain
Click here for TYGACIL®(tigecycline) Prescribing Information in Northern Ireland
Click here for AMIKACIN (amikacin sulfate)  Prescribing Information
PP-UNP-GBR-5793. July 2023
Join us!

Follow the link to learn about out upcoming meetings and online webinars event - dates, location and agendas.

Register here Loading

Adverse events should be reported. Reporting forms and information can be found at or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


Copyright © 2023 Pfizer Limited. All rights reserved.


VAT registration number GB201048427

PP-UNP-GBR-4885. May 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
You are now leaving PfizerPro
​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021